Diagnostic center is a place where different medical examinations are carried. A diagnosis or medical examinations are done on patient to check whether the body is carrying any disease or symptoms. Based on the diagnosis, treatment is given to the patient accordingly.
Oncquest is a well known testing lab which has its Pathology diagnostic labs in Mumbai and other parts of India. We at Oncquest are delivering over 30 million tests a year, catering to more than 20,000 medical Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants.
We are a dynamic and constantly improving laboratory center, providing reliable pathology services to our clients and patients. We strive to produce extremely satisfactory results by keeping in touch with the latest developments in the field of pathology
We implement the latest technology available and our labs are equipped with molecular technology including fields such as bioinformatics, pharmocogenomics, companion diagnostics, proteomics and biomarker studies. We are also equipped with an integrated research facility and an advanced genetic oncology wing, thus expanding our scope of testing.
We are a certified and accredited cancer diagnosis lab by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathology (CAP).
FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.
FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.
select introns profiled
BRCA1 & BRCA2 are genes that produce tumor suppressor proteins & play a role in ensuring the stability of the cell’s genetic material.
The MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The MammaPrint Test is used in two ways:
Who’s eligible for the MammaPrint test?
MammaPrint can only be used to analyze early-stage breast cancers that are:
In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.
How does the MammaPrint test work?
The MammaPrint test looks at the activity of 70 genes and then calculates a recurrence score that is either low risk or high risk.
If a patient decide to have the MammaPrint test, a patient and a patient’s doctor will consider a number of factors when deciding on whether to add chemotherapy to a patient treatment plan, including:
MET GENE TESTING FOR LUNG CANCER
A circulating tumor cell has sloughed off cancerous tissue and moves through the bloodstream to a new site.Circulating Tumor Cells Assay
Panorama is the most advanced Non-Invasive Pre Natal Test(NIPT) performed on maternal blood to screen the most common fetal chromosome abnormalities such as t21, t18, t13, Monosomy X, Triploidy and Microdeletions.
Next Generation Sequencing (NGS)
A highly sensitive technology, which can detect mutations in samples having as low as 5% tumor cells. It can be multiplexed that is many genes can be targeted at the same time, thus detecting various mutations in the same assay. Each DNA nucleotide is read several times (100-1000 times) which adds to the specificity of the assay. This platform provides accurate, reliable data and excellent coverage.
Advantages of NGS
“World class facilities available under one roof”
Oncquest has one of the widest test portfolios in the diagnostic industry especially in exploratory & end-point biomarkers, genomic services & histology. Our ten years of molecular testing experience & accomplishments has enabled us to adapt to market trends & customer requirements and hence have been able to develop tests based on the protocol requirements. Our encouraging team & flexible organizational structure equips us to evaluate exploratory biomarkers. We develop & validate biomarkers based on wide range of technologies possessed by Oncquest. We have launched many molecular tests in Indian market.Read More
Oncquest offers more than 1000 assays spanning the screening, diagnostic, monitoring and prognostic spectra of laboratory assays from Oncology to Infectious diseases on the Quality guidelines of NABL and College of American Pathologists (CAP).
Our Specialised Capabilities are:– Molecular Pathology
– Cytogenetics and FISH
– Haematology & Flow Cytometry
– Immunohistochemistry (IHC)
– Surgical Pathology
– Next Generation Sequencing(NGS)
To view other details, Please click here.General Pathology –
Oncquest offers more than 1000 assays for clinical diagnosis spanning diagnostic, monitoring and prognostic spectra of assays for all your
|Date||24 November 2018|
|Event||ESMO Asia 2018 Congress|
|Session||Poster display - Cocktail|
|Topics||Bioethics, Legal, and Economic Issues|
|Citation||Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426|
|Authors||M. Bakre Author Affiliations|
Current molecular risk stratification tests have helped clinicians to optimize chemotherapy for hormone receptor positive, HER2 negative early stage breast cancer patients leading to huge savings in treatment costs and improved quality of life. However, current tests are not impactful in the Asian subcontinent due to the extreme cost-sensitivity of the market. Aim of this study was to develop and validate a simple, cost-effective and accurate test based on insightful biomarkers involved in tumor recurrence using robust statistical methodology to stratify patients based on risk of recurrence.Methods
A retrospective cohort of 300 patients, was used to develop ‘CanAssist-Breast’(CAB)- an immunohistochemistry based test comprising 5 biomarkers plus three clinical parameters (Tumor size, node status and grade) using machine learning based algorithm. Retrospective clinical validation on 850+ cases was performed and Kaplan Meier survival analysis, multivariate analysis was performed to assess robustness of the test.Results
CanAssist-Breast classifies patients into ‘low or high’ risk of recurrence based on recurrence score on a scale of 1-100 with a cut off at 15.5. Clinical validation of CAB showed distant metastasis-free survival (DMFS) was significantly different between low- (DMFS: 95%) and high-risk (DMFS 80%) groups in the validation cohort treated with hormone therapy alone (n = 195) and in the entire validation cohort of 857 patients as well. In multivariate analysis, CAB risk score was the most significant independent predictor of distant recurrence with a hazard ratio of 4.25 (P = 0.009). Patients stratified as high-risk by CAB have 19% chemotherapy benefit. We also show that CAB can further identify discrete low- and high-risk sub-groups within IHC4 intermediate risk group and also in a node and age independent manner.Conclusions
To our knowledge, CAB is the first machine learning based prognostic risk of recurrence prediction classifier using a combination of unique biomarkers and clinicopathological parameters. We believe that CAB enables accurate treatment planning in early stage HR+/HER2- breast cancer patients in low-resource settings.Editorial acknowledgementClinical trial identificationLegal entity responsible for the study